Mechanism of Vpu action: the rest of the story
Vpu 作用机制:故事的其余部分
基本信息
- 批准号:8848757
- 负责人:
- 金额:$ 22.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-05-15 至 2017-04-30
- 项目状态:已结题
- 来源:
- 关键词:Antiviral AgentsAntiviral TherapyBindingBiological AssayCD4 AntigensCell membraneCell surfaceCellsComplexCullin 1Cytoplasmic TailDisputesEmployee StrikesEndoplasmic ReticulumEndosomesF Box DomainF-Box ProteinsFailureGibbon Ape Leukemia VirusGlycoproteinsGolgi ApparatusHIVHIV-1Host DefenseInfectionInterferonsLeadLigaseMembraneModelingObservational StudyPhenotypePhysiologicalPlayProcessProductionProteinsRecruitment ActivityRecyclingRestRoleSurfaceUrsidae FamilyViralViral PhysiologyVirusVirus AssemblyWorkbasecofactormulticatalytic endopeptidase complexnoveloverexpressionpandemic diseaseparticlepreventpublic health relevancereceptorsuperinfectiontherapeutic developmenttraffickingubiquitin ligaseubiquitin-protein ligasevpu Protein
项目摘要
DESCRIPTION (provided by applicant): The HIV accessory protein Vpu is known to modulate two host proteins, CD4 and BST-2, but it is thought to do so by two completely different mechanisms. CD4 is believed to be targeted in the endoplasmic reticulum for proteasomal degradation, while BST-2 is believed to be targeted in the Golgi apparatus and the recycling endosomes for lysosomal degradation. Both targets are believed to interact with cellular Skp-Cullin1-F-box (SCF) E3 ligases to facilitate their action, but it is disputed which kinds of SCF ligase act as co-factors. SCF ligases that contain the F- box proteins ssTRCP-1 or -2 are believed to be two potential Vpu cofactors, but some suggest that there are additional forms of the ligase that have not yet been identified. Because different assays are typically used to study these two Vpu targets, it has been difficult to draw direct parallels between them. In particular, the assays used to study CD4 are performed under conditions where Vpu is expressed at levels much higher than would be found in a normal infection. The glycoprotein from Gibbon ape leukemia virus (GaLV Env) has recently been identified as an additional Vpu target. Based on recognition parameters, GaLV Env appears to be analogous to CD4, but based on its mechanism of action, it appears more analogous to BST-2. Vpu requires an SCF ligase to target GaLV Env, but ssTRCP-1 and -2 are dispensable. In addition, CD4 expression was found to restrict HIV-1 infectivity under particular conditions in a BST-2 and HIV Env independent fashion, but this restriction could be alleviated by Vpu. A novel assay has been developed based on this observation for studying Vpu targeting of CD4 at physiological concentrations. It is hypothesized that CD4, BST-2, and GaLV Env are all modulated by a single mechanism and that there is a previously unidentified F-box protein that plays a critical role in this modulation An infectivity-based assay will be used to identify the SCF ligase used by Vpu to target GaLV Env, and characterize the importance of this ligase in the modulation of all three Vpu targets. The work will be divided into the following specific aims: Aim 1. To determine how CD4 restricts viral infectivity in the absence of HIV-1 Env and how Vpu overcomes this restriction. Aim 2. To identify the F-box protein used by Vpu to modulate GaLV Env and to determine if this F-box protein also functions in the modulation of CD4 and BST-2. These studies will answer fundamental questions about the mechanism of HIV-1 Vpu activity and could open up new avenues for the development of therapeutic antivirals.
描述(由申请人提供):已知HIV辅助蛋白Vpu调节两种宿主蛋白,CD4和BST-2,但它被认为是通过两种完全不同的机制来调节的。CD4被认为是内质网蛋白酶体降解的靶标,而BST-2被认为是高尔基体和循环内体溶酶体降解的靶标。这两种靶标都被认为与细胞Skp-Cullin1-F-box (SCF) E3连接酶相互作用以促进其作用,但哪种SCF连接酶作为辅助因子存在争议。含有F- box蛋白ssTRCP-1或-2的SCF连接酶被认为是两种潜在的Vpu辅助因子,但一些人认为还有其他形式的连接酶尚未被鉴定。由于通常使用不同的测定方法来研究这两种Vpu靶点,因此很难在它们之间得出直接的相似之处。特别是,用于研究CD4的检测是在Vpu表达水平远高于正常感染水平的条件下进行的。长臂猿白血病病毒(GaLV Env)的糖蛋白最近被确定为一个额外的Vpu靶标。从识别参数上看,GaLV Env与CD4类似,但从作用机制上看,它更类似于BST-2。Vpu需要SCF连接酶靶向GaLV Env,但ssTRCP-1和-2是可有可无的。此外,CD4表达在特定条件下以BST-2和HIV Env独立的方式限制HIV-1的感染,但Vpu可以缓解这种限制。基于这一观察结果,一种新的检测方法被开发出来,用于研究Vpu在生理浓度下靶向CD4。假设CD4, BST-2和GaLV Env都是由单一机制调节的,并且存在一种先前未被识别的F-box蛋白在这种调节中起关键作用。基于感染的检测将用于鉴定Vpu靶向GaLV Env的SCF连接酶,并表征该连接酶在所有三个Vpu靶点调节中的重要性。这项工作将分为以下具体目标:目标1。确定在HIV-1 Env缺失的情况下,CD4如何限制病毒的传染性,以及Vpu如何克服这种限制。目标2。目的鉴定Vpu调节GaLV Env的F-box蛋白,并确定该F-box蛋白是否也参与CD4和BST-2的调节。这些研究将回答有关HIV-1 Vpu活性机制的基本问题,并可能为开发治疗性抗病毒药物开辟新的途径。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
- DOI:10.3390/v10100573
- 发表时间:2018-10-19
- 期刊:
- 影响因子:0
- 作者:Song YE;Cyburt D;Lucas TM;Gregory DA;Lyddon TD;Johnson MC
- 通讯作者:Johnson MC
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc C Johnson其他文献
Marc C Johnson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc C Johnson', 18)}}的其他基金
Mechanism of Vpu action: the rest of the story
Vpu 作用机制:故事的其余部分
- 批准号:
8789061 - 财政年份:2014
- 资助金额:
$ 22.61万 - 项目类别:
Mechanistic studies of an unexpected HIV-1 Vpu function
HIV-1 Vpu 意外功能的机制研究
- 批准号:
8011894 - 财政年份:2010
- 资助金额:
$ 22.61万 - 项目类别:
Mechanistic studies of an unexpected HIV-1 Vpu function
HIV-1 Vpu 意外功能的机制研究
- 批准号:
8071196 - 财政年份:2010
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
7924267 - 财政年份:2009
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
7545909 - 财政年份:2008
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
8204753 - 财政年份:2008
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
7417746 - 财政年份:2008
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
7749936 - 财政年份:2008
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
7998179 - 财政年份:2008
- 资助金额:
$ 22.61万 - 项目类别:
Elucidation of HIV Env acquisition strategies
HIV Env 获取策略的阐明
- 批准号:
8657748 - 财政年份:2006
- 资助金额:
$ 22.61万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 22.61万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 22.61万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 22.61万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 22.61万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 22.61万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 22.61万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 22.61万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 22.61万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 22.61万 - 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
- 批准号:
20K08371 - 财政年份:2020
- 资助金额:
$ 22.61万 - 项目类别:
Grant-in-Aid for Scientific Research (C)